Drug intelligence / Profile preview

Yonsei Univ. College of Medicine SDHC compound 10

Development stage: Unknown
Lead developer: Yonsei University College of Medicine

Overview

Yonsei Univ. College of Medicine SDHC compound 10: sourced facts only. name: "Mechanistic studies showed that both 10 and 17 inhibit SDHC activity, reduce CII-specific oxygen consumption rates (OCR), and induce increased ROS production, leading to apoptosis." [PMID:40882437]; target: "Mechanistic studies showed that both 10 and 17 inhibit SDHC activity, reduce CII-specific oxygen consumption rates (OCR), and induce increased ROS production, leading to apoptosis." [PMID:40882437]; developer: "Department of Biomedical Sciences, Graduate School of Medical Science, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea." [PMID:40882437]

Targets

SDHC (Succinate dehydrogenase cytochrome b560 subunit)

Beyond the preview

Go deeper on Yonsei Univ. College of Medicine SDHC compound 10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yonsei Univ. College of Medicine SDHC compound 10.